Ingredients by Nature (IBN), a supplier of customisable science-based food ingredients, has announced approval by the USPTO of a second patent for the company’s use of eriocitrin in its ingredient formulations, including Eriomin.
The eriocitrin patent claim is for a “method of increasing GLP-1 levels in a subject in need thereof, comprising administering a composition comprising eriocitrin to the subject.” GLP-1 helps to maintain appropriate amounts of insulin secretion and glucose uptake. The patent is hoped to further solidify the use of eriocitrin to support individuals with unhealthy levels of fasting blood glucose, such as prediabetics, by administering 50-600 mg of the citrus flavonoid for increased GLP-1 levels.
This announcement is in addition to the recent approval for an amendment of IBN’s previous eriocitrin patent #10596185. The revision has widened the dosage claim of eriocitrin from 100-200 mg to 25-800 mg for the lowering of glucose levels.
“There are multiple facets to prediabetes management and increasing GLP-1 plays a vital role in helping to support healthy blood glucose levels,” said Rob Brewster, President of IBN. “The approval of our second eriocitrin patent provides strong support for our efforts to raise awareness of the flavonoid’s multi-faceted potential. We also have several more very promising human clinicals in process and hope to see some of them published soon.”
Eriocitrin is the primary citrus flavonoid used in IBN’s Eriomin ingredients. Two versions of Eriomin are currently available, Eriomin Glucose for prediabetes management and Esport for a healthy gaming lifestyle, which help maintain blood glucose levels within the normal range.
